Morning Buzz: Tesla Motors (TSLA), Geron (GERN), Acadia Pharmaceuticals (ACAD), Twitter (TWTR)

Wall Street

Shares of Tesla Motors (TSLA) are up slightly this morning following a tweet from CEO Elon Musk saying Tesla’s Model 3 production will begin in 2 years and will cost $35K. Musk also said that for the Model X, “First production cars will be handed over on September 29 at [Tesla’s] Fremont factory”.

Shares of Geron Corporation (GERN) are higher by nearly 23% to $3.74 in pre-market trading on Thursday after the company announced publication of two papers in ‘The New England Journal of Medicine’ that highlight the transformative potential of Imetelstat in Hematologic Myeloid Malignancies.

“The data in the ET and MF study publications in The New England Journal of Medicine provide compelling evidence that use of a telomerase inhibitor, such as imetelstat, may result in ground-breaking changes in how we approach the future treatment of hematologic myeloid malignancies,” stated John A. Scarlett, Geron’s President and CEO.

Acadia Pharmaceuticals (ACAD) shares surged 9.14% to $41.55 in pre-market trading after announcing the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease.

Shares of Twitter, Inc. (TWTR) are up slightly this morning. The board of the San Francisco-based social-media company meets today and the focus will be on whether the firm will make any announcement on the selection of a new CEO. Twitter co-founder Jack Dorsey became Twitter’s interim CEO in June after the resignation of CEO Dick Costolo. Since the company started searching for a new chief executive officer, the stock has plunged 22%.

Create Content With AI

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


*

This site uses Akismet to reduce spam. Learn how your comment data is processed.